ERBB2 and breast carcinoma: In addition, disitamab vedotin as monotherapy or combination therapy is also in clinical trials for the treatment of other solid tumors, including urothelial cancer, biliary tract cancer, non-small cell lung cancer, and HER2-positive and HER2-low-expressing breast cancers.